Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) on Monday announced the the re availability of Zenatane (Isotretinoin Capsules, USP) in 10 mg, 20 mg, 30 mg and 40 mg following approval by the US Food and Drug Administration (USFDA) to treat severe acne as well as prevent certain skin cancers.
The Zenatane (Isotretinoin Capsules, USP) in 10 mg, 20 mg, 30 mg and 40 mg is reportedly the therapeutic equivalent generic version of Accutane and is being launched under an approved Risk Evaluation and Mitigation Strategy (REMS) Programme as well as the US FDA's special restricted iPLEDGE distribution programme.
For the most recent 12 months ending in March 2019, the company's Zenatane (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg brand and generic had US sales of approximately USD525m MAT, according to IQVIA Health.
In addition, the company's Zenatane (Isotretinoin Capsules, USP) are available in 3x10 (30-count) blister packages of 10 mg, 20 mg 30 mg, and 40 mg Capsules, USP.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval